GlassScriptPhysician profile
Catherine A Gianan
NPI 1174616320
$9,944.81
in general payments reported to CMS, 2019-2025
31 companies · $2,947 in 2025
The $2,947 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,069 · 2022: $1,324 · 2023: $2,417 · 2024: $2,189 · 2025: $2,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,412 · Travel and Lodging: $902 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,411.94 |
| Travel and Lodging | $901.88 |
| Education | $238.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,811.00 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,314.70 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,289.43 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $915.10 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $770.08 | 2021 | |
| Axsome Therapeutics, INC. | $525.46 | 2023-2025 | Auvelity |
| Tris Pharma INC | $460.81 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Alkermes, INC. | $383.91 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $346.71 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $288.48 | 2021-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $231.30 | 2022-2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $209.48 | 2023-2024 | Jornay Pm |
| Corium, LLC | $187.54 | 2022-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $173.06 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $161.82 | 2022-2025 | Ingrezza |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $140.69 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Scientific Affairs, LLC | $117.27 | 2024 | Spravato |
| Merck Sharp & Dohme LLC | $90.72 | 2022-2023 | Belsomra |
| Noven Therapeutics, LLC | $76.16 | 2024 | Xelstrym |
| Vanda Pharmaceuticals INC. | $64.72 | 2022-2023 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $59.91 | 2021-2024 | Loreev Xr |
| Indivior INC. | $53.77 | 2024 | Sublocade |
| Idorsia Pharmaceuticals US INC | $45.40 | 2022-2024 | Quviviq |
| Bausch Health US, LLC | $43.53 | 2022-2023 | Aplenzin, Wellbutrin |
| Neuronetics, INC. | $41.74 | 2024-2025 | Neurostar Tms Therapy System |
| E.R. Squibb & Sons, L.L.C. | $38.57 | 2025 | Cobenfy |
| Harmony Biosciences LLC | $34.66 | 2023 | Wakix |
| Braeburn INC. | $18.79 | 2024 | Brixadi |
| Hikma Pharmaceuticals USA | $16.97 | 2022 | |
| Neos Therapeutics, LP | $16.79 | 2025 | Exxua |
| Adlon Therapeutics L.P. | $16.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Gianan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.